BBH

BBH: Buy Rating, As Tech Investors Look Beyond FAANG

VanEck Biotech ETF tracks top U.S.-listed biotech companies, offers exposure to innovative therapies and technologies. Biotechnology sector experiencing exponential growth driven by emerging technologies addressing global challenges. The VanEck biotech ETF (BBH) is under-discovered compared to peers, offers potential for trend change in biotech sector.

Weekly Report: what happened at BBH last week (0715-0719)?

Biogen Earnings Preview: What to Expect

Biogen Inc. Is set to announce its fiscal Q2 earnings results before the market opens on Thursday, Aug. 1. The company is renowned for its innovative therapies for neurological and neurodegenerative diseases. Biogen reported its Q1 earnings on Apr. 24. BIIB stock is down 11.8% on a YTD.

What You Need to Know Ahead of Amgen's Earnings Release

Amgen Inc. Is set to announce its fiscal Q2 earnings results after the market closes on Tuesday, Aug. 6. The company is expected to report a profit of $4.87 per share. Amgen stock is up 15.7% on a YTD basis.

ASCO Annual Meeting 2024: Breakthrough Treatments Hint At Renewed Hope For Patients And Investors

Weekly Report: what happened at BBH last week (0708-0712)?

Q3 2024 Equity Market Outlook

Home Market Outlook Today's Market Q3 2024 Equity Market Outlook: Neuberger Berman 2.93K Followers. We expect further corporate earnings growth across sectors, fueled by rising household net worth and a global industrial rebound. We recommend overweighting technology, communications and consumer discretionary stocks.

Weekly Report: what happened at BBH last week (0701-0705)?